SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Sara Marceglia, Elena Rossi, Manuela Rosa, Filippo Cogiamanian, Lorenzo Rossi, Laura Bertolasi, Alberto Vogrig, Francesco Pinciroli, Sergio Barbieri, Alberto Priori, Web-Based Telemonitoring and Delivery of Caregiver Support for Patients With Parkinson Disease After Deep Brain Stimulation: Protocol, JMIR Research Protocols, 2015, 4, 1, e30

    CrossRef

  2. 2
    Livia Dézsi, László Vécsei, Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs, Expert Opinion on Drug Metabolism & Toxicology, 2014, 10, 3, 409

    CrossRef

  3. 3
    Matthias Löhle, Carl-Johan Ramberg, Heinz Reichmann, Anthony H. V. Schapira, Early Versus Delayed Initiation of Pharmacotherapy in Parkinson’s Disease, Drugs, 2014, 74, 6, 645

    CrossRef

  4. 4
    Ronald N. Kostoff, Literature-related discovery: common factors for Parkinson’s Disease and Crohn’s Disease, Scientometrics, 2014, 100, 3, 623

    CrossRef

  5. 5
    Rashmi Lakshminarayana, Duolao Wang, David Burn, K Chaudhuri, Gemma Cummins, Clare Galtrey, Bruce Hellman, Suvankar Pal, Jon Stamford, Malcolm Steiger, Adrian Williams, Smartphone- and internet-assisted self-management and adherence tools to manage Parkinson’s disease (SMART-PD): study protocol for a randomised controlled trial (v7; 15 August 2014), Trials, 2014, 15, 1, 374

    CrossRef

  6. 6
    Massimo S. Fiandaca, Robert M. Padilla, Ishmeal Conteh, Howard J. Federoff, Can population genomics guide future therapeutic gene transfer strategies for Parkinson’s disease?, Open Journal of Genetics, 2013, 03, 02, 19

    CrossRef

  7. 7
    Brian P. Dranka, Alison Gifford, Anamitra Ghosh, Jacek Zielonka, Joy Joseph, Anumantha G. Kanthasamy, Balaraman Kalyanaraman, Diapocynin prevents early Parkinson's disease symptoms in the leucine-rich repeat kinase 2 (LRRK2R1441G) transgenic mouse, Neuroscience Letters, 2013, 549, 57

    CrossRef

  8. 8
    Giselle M Petzinger, Beth E Fisher, Sarah McEwen, Jeff A Beeler, John P Walsh, Michael W Jakowec, Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease, The Lancet Neurology, 2013, 12, 7, 716

    CrossRef

  9. 9
    Kai-Yin Chau, J. Mark Cooper, Anthony Henry V. Schapira, Pramipexole Reduces Phosphorylation of α-Synuclein at Serine-129, Journal of Molecular Neuroscience, 2013, 51, 2, 573

    CrossRef

  10. 10
    Anthony HV Schapira, Mitochondrial diseases, The Lancet, 2012, 379, 9828, 1825

    CrossRef

  11. 11
    B.R. Bloem, F. Stocchi, Move for Change Part I: a European survey evaluating the impact of the EPDA Charter for People with Parkinson’s disease, European Journal of Neurology, 2012, 19, 3
  12. 12
    Jianfei Chao, Yen Leung, Mingfu Wang, Raymond Chuen-Chung Chang, Nutraceuticals and their preventive or potential therapeutic value in Parkinson's disease, Nutrition Reviews, 2012, 70, 7
  13. 13
    Yoland Smith, Thomas Wichmann, Stewart A Factor, Mahlon R DeLong, Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa, Neuropsychopharmacology, 2012, 37, 1, 213

    CrossRef

  14. 14
    Anthony Henry Vernon Schapira, Targeting Mitochondria for Neuroprotection in Parkinson's Disease, Antioxidants & Redox Signaling, 2012, 16, 9, 965

    CrossRef

  15. 15
    Giuseppa Mudò, Johanna Mäkelä, Valentina Di Liberto, Timofey V. Tselykh, Melania Olivieri, Petteri Piepponen, Ove Eriksson, Annika Mälkiä, Alessandra Bonomo, Minna Kairisalo, Jose A. Aguirre, Laura Korhonen, Natale Belluardo, Dan Lindholm, Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson’s disease, Cellular and Molecular Life Sciences, 2012, 69, 7, 1153

    CrossRef

  16. 16
    Anthony H. V. Schapira, Aetiopathogenesis of Parkinson’s disease, Journal of Neurology, 2011, 258, S2, 307

    CrossRef

  17. 17
    A. H. V. Schapira, Challenges to the development of disease-modifying therapies in Parkinson’s disease, European Journal of Neurology, 2011, 18,
  18. 18
    Anthony H. Schapira, Peter Jenner, Etiology and pathogenesis of Parkinson's disease, Movement Disorders, 2011, 26, 6
  19. You have free access to this content19
    Anthony H. V. Schapira, Mitochondrial Pathology in Parkinson's Disease, Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 2011, 78, 6
  20. 20
    Anthony H.V. Schapira, Monoamine Oxidase B Inhibitors for the Treatment of Parkinsonʼs Disease, CNS Drugs, 2011, 25, 12, 1061

    CrossRef

  21. 21
    E. K. Tan, A. H. Schapira, New LRRK2 variants identified in Parkinson’s disease, European Journal of Neurology, 2011, 18, 3
  22. 22
    Paul M. A. Antony, Nico J. Diederich, Rudi Balling, Parkinson’s disease mouse models in translational research, Mammalian Genome, 2011, 22, 7-8, 401

    CrossRef

  23. 23
    A. H. V. Schapira, The management of Parkinson’s disease – what is new?, European Journal of Neurology, 2011, 18,
  24. 24
    David J Daley, Katherine HO Deane, Richard J Gray, Paul F Worth, Allan B Clark, Kanagasabesan Sabanathan, Michael Pfeil, Phyo K Myint, The use of carer assisted adherence therapy for people with Parkinson's disease and their carers (CAAT-PARK): study protocol for a randomised controlled trial, Trials, 2011, 12, 1, 251

    CrossRef

  25. 25
    Anthony H. V. Schapira, Eduardo Tolosa, Molecular and clinical prodrome of Parkinson disease: implications for treatment, Nature Reviews Neurology, 2010, 6, 6, 309

    CrossRef

  26. 26
    Neurology in the European Journal of Neurology, European Journal of Neurology, 2010, 17, 12
  27. 27
    Alice Cronin-Golomb, Parkinson’s Disease as a Disconnection Syndrome, Neuropsychology Review, 2010, 20, 2, 191

    CrossRef

  28. 28
    Karen L. O'Malley, The Role of Axonopathy in Parkinson's Disease, Experimental Neurobiology, 2010, 19, 3, 115

    CrossRef

  29. 29
    Anthony H.V. Schapira, Neuroprotection in Parkinson's disease, Parkinsonism & Related Disorders, 2009, 15, S41

    CrossRef

  30. 30
    Kurt A. Jellinger, Parkinson's Disease,